Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies.

Background: Rotigotine is a potent and selective D1, D2, and D3 dopaminergic receptor agonist. Due to an extensive first-pass effect, it has a very low oral bioavailability (approximately 0.5% in rats).